17:11 EST Crescent Biopharma (CBIO) files to sell 19.71M shares of common stock for holders
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CBIO:
- Crescent Biopharma: Advancing De-Risked Immuno-Oncology Pipeline and Strategic Partnerships Underscore Undervalued Buy Opportunity
- Crescent Biopharma announces regulatory clearance of IND applications
- Two new option listings and eighteen option delistings on December 22nd
- Crescent Biopharma’s Strategic Growth and Competitive Edge Justify Buy Rating
- Crescent Biopharma price target raised to $32 from $28 at Stifel